Navigation Links
HIV drug resistance increasing in UK and among highest in the world

Those infected with HIV in the UK have one of the highest rates of resistance to anti-HIV drugs of anywhere in the world, prompting fears of a second wave epidemic of resistant virus, a new study claims in this week's BMJ.

The study authors are concerned that the large reductions in deaths and improvements to health since people with HIV were given combinations of drugs (combination antiretroviral therapy) may be compromised because of this.

Using national data on HIV positive cases, the researchers tested patients for resistance to the antiretroviral drugs before embarking on the treatment. Tests were conducted on 2,357 patients between 1996 and 2003 ?thus researchers could track if there were changes to resistance patterns as time went on.

They found that 335 people showed some degree of resistance to one or more antiretroviral drugs in total. Most of these people ?257 ?were resistant to drugs within one class only, 44 cases showed resistance to drugs within two classes and 34 showed resistance to drugs within all three commonly used drug classes.

Overall, this equates to a 14% rate of resistance to one or more of these drugs among the group studied over the whole time period. The resistance had reached an estimated 19% for the most recent time period of 2002-2003.

The UK's 14% rate of resistance was considerably higher than the 7% estimate for chronically infected patients in the USA, 6% in France and 10% elsewhere in Europe. Direct comparisons should be treated cautiously, however, as different studies have used different definitions of resistance. Using a more conservative definition of resistance (high level resistance to at least one drug) gives an overall estimate of 9% for the UK for the years 1996-2003, with the rate being 12% in 2002-3.

The authors say: 'The United Kingdom has among the highest reported rates of primary resistance to HIV drugs worldwide. By limiting the therapeutic options for a significant number of patients, the secondary epidemic of drug resistant HIV represents a major clinical and public health problem.'


'"/>

Source:BMJ-British Medical Journal


Related biology news :

1. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
2. Researchers make gains in understanding antibiotic resistance
3. MUHC scientists describe genetic resistance to rampant virus
4. New polysaccharide may help combat multidrug resistance in cancer
5. New book explains antibiotic resistance for a broad audience
6. Insects develop resistance to engineered crops
7. Retroviral resistance gene found
8. Drug resistance testing in treatment-naive HIV patients is cost-effective
9. Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance
10. Gaining ground in the race against antibiotic resistance
11. Genes linked to treatment resistance in children with leukemia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology: